You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 康寧傑瑞製藥-B(9966.HK)漲超7% KN046五項註冊臨牀積極推進中
格隆匯 11-12 15:09
格隆匯11月12日丨康寧傑瑞製藥-B(9966.HK)午後漲幅擴大至7.24%,近日自底部反彈達15%。現報16.1港元,總市值152.5港元。興業證券指出,公司KN046五項註冊臨牀推進迅速,適應症佈局多元化且市場潛力巨大。目前KN046 已有四項適應症處於註冊性臨牀階段。包括一線鱗狀NSCLC、PD-(L)1 經治NSCLC、一線胰腺癌及後線胸腺癌。另外,公司有望在2022年上半年正式啟動一線肝癌的註冊性臨牀。該行又稱,由於首席商務官韓淨加盟,將加速KN046 和後續重磅產品的商業化進程。維持其“買入”評級並看高目標價至27.15港元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account